Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2020 Nov;31(11):2499-2501.
doi: 10.1681/ASN.2020081182. Epub 2020 Sep 11.

Binder Blunder in CKD

Joachim H Ix  1
Affiliations
Editorial

Binder Blunder in CKD

Joachim H Ix. J Am Soc Nephrol. 2020 Nov.
No abstract available

Keywords: mineral metabolism.

PubMed Disclaimer

Comment on

  • A Randomized Trial on the Effect of Phosphate Reduction on Vascular End Points in CKD (IMPROVE-CKD).
    Toussaint ND, Pedagogos E, Lioufas NM, Elder GJ, Pascoe EM, Badve SV, Valks A, Block GA, Boudville N, Cameron JD, Campbell KL, Chen SSM, Faull RJ, Holt SG, Jackson D, Jardine MJ, Johnson DW, Kerr PG, Lau KK, Hooi LS, Narayan O, Perkovic V, Polkinghorne KR, Pollock CA, Reidlinger D, Robison L, Smith ER, Walker RJ, Wang AYM, Hawley CM; IMPROVE-CKD Trial Investigators. Toussaint ND, et al. J Am Soc Nephrol. 2020 Nov;31(11):2653-2666. doi: 10.1681/ASN.2020040411. Epub 2020 Sep 11. J Am Soc Nephrol. 2020. PMID: 32917784 Free PMC article. Clinical Trial.

References

    1. Block GA, Ix JH, Ketteler M, Martin KJ, Thadhani RI, Tonelli M, et al.: Phosphate homeostasis in CKD: Report of a scientific symposium sponsored by the National Kidney Foundation. Am J Kidney Dis 62: 457–473, 2013. - PubMed
    1. Kidney Disease Improving Global Outcomes (KDIGO) : KDIGO 2018. clinical practice guidelines update for the diagnosis, evalutation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Available at: https://kdigo.org/wp-content/uploads/2017/02/2017-KDIGO-CKD-MBD-GL-Updat.... Accessed August 8, 2020
    1. Toussaint N, Pedagogos E, Lioufas NM, Elder G, Pascoe EM, Badve SV, et al. : Impact of Phosphate Reduction on Vascular End-Points in Chronic Kidney Disease (IMPROVE-CKD): A randomized, placebo-controlled trial. J Am Soc Nephrol 31: 2653–2666, 2020 - PMC - PubMed
    1. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, et al.: Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 23: 1407–1415, 2012. - PMC - PubMed
    1. Ix JH, Isakova T, Larive B, Raphael KL, Raj DS, Cheung AK, et al.: Effects of nicotinamide and lanthanum carbonate on serum phosphate and fibroblast growth factor-23 in CKD: The COMBINE trial. J Am Soc Nephrol 30: 1096–1108, 2019. - PMC - PubMed